Welcome to our dedicated page for Livanova news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova stock.
LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
Summary not available.
Summary not available.
LivaNova PLC (Nasdaq: LIVN) announced the resignation of CEO Damien McDonald, effective immediately. William A. Kozy, Chair of the Board, will serve as interim CEO while the company searches for a permanent replacement. Kozy brings significant experience from his career at Becton Dickinson and as Vice Chair at The Cooper Companies. The company also reported preliminary Q1 2023 revenue of $263 million, marking a 9% increase compared to $240 million in Q1 2022. LivaNova is committed to maintaining its focus on growth and innovation during this transition, with full results set to be released on May 3, 2023.
LivaNova PLC (Nasdaq: LIVN) will host a conference call to discuss its first-quarter 2023 results on May 3, 2023, at 1 p.m. London time (8 a.m. Eastern Time). The results will be released prior to the call, and a live audiocast will be accessible on the company's website. Investors can join by dialing the respective numbers for the U.S. and international callers. The company has nearly five decades of experience in the medical technology sector and operates in over 100 countries. A replay of the call will be available on their website for 90 days.
LivaNova PLC (NASDAQ: LIVN) has received FDA 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM), marking the start of its commercial launch in the U.S. The company also secured approvals from Health Canada and the Japanese PMDA, initiating a broader commercial release in Europe. The Essenz Perfusion System enhances clinical workflows and patient care during cardiopulmonary bypass (CPB) procedures, featuring reliable technology based on the LivaNova S5™ HLM. Key benefits include individualized patient care, user-friendly interfaces, and robust support worldwide.
LivaNova PLC (Nasdaq: LIVN) has announced that its Chief Executive Officer, Damien McDonald, will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The event is scheduled for 9 a.m. Eastern Time on Thursday, March 16. Interested parties can register for the webcast through www.livanova.com/events, with a replay available on the company's website for 90 days after the presentation. LivaNova is a global medical technology company dedicated to improving patient outcomes with innovative solutions.
LivaNova PLC (Nasdaq: LIVN) reported Q4 2022 revenue of $274.9 million, up 1.8% year-over-year, with adjusted diluted EPS at $0.81. For full-year 2022, revenue was $1.02 billion, down 1.3%, but showed a 2.3% rise when excluding the Heart Valve business divested in 2021. The Cardiopulmonary segment grew 10.5%, driven by increased cardiac surgeries. However, Advanced Circulatory Support revenue fell 29.1% due to fewer ECMO treatments. Looking ahead, LivaNova expects 2023 revenue growth of 3-5% and adjusted diluted EPS between $2.45 and $2.65. The company also ceased its heart failure clinical study due to disappointing data.
LivaNova PLC (Nasdaq: LIVN) has initiated a limited commercial release of the Essenz™ Perfusion System in select European centers, following positive clinical experiences at Catharina Hospital in the Netherlands and San Donato Hospital in Italy. The innovative system integrates a next-generation heart-lung machine and a patient monitor, focusing on providing data-driven, personalized support during cardiopulmonary bypass procedures. Both components have received CE Mark, with further regulatory approvals pending in key regions. The release marks a significant advance in perfusion technology, emphasizing safety and operational flexibility.
LivaNova PLC has launched the SenTiva DUO, an implantable pulse generator designed to provide VNS Therapy for drug-resistant epilepsy. This new device features a dual-pin header, allowing existing patients with dual-pin systems to upgrade without lead revision. It maintains the therapeutic advantages of the original SenTiva, including automatic seizure response and programmable therapy options. The device has received 510(k) clearance from the U.S. FDA and is now available in the U.S. market, aiming to enhance patient care for those requiring advanced epilepsy treatment.
LivaNova PLC (NASDAQ: LIVN) will host a conference call on February 22, 2023, at 1 p.m. London time to discuss its fourth-quarter and full-year 2022 results. The results will be released prior to the call. The audiocast can be accessed via www.livanova.com/events. Participants can join via telephone by calling +1 844 200 6205 (U.S.) or +1 929 526 1599 (international), with access code 041577. A replay will be available for 90 days after the call. LivaNova is a global leader in medical technology, focused on delivering innovative solutions for patients and healthcare systems worldwide.